

## Change in number of shares and votes in Ascelia Pharma AB

During the month of February, the number of shares and votes in Ascelia Pharma AB have changed due to conversion of a total of 54,500 series C shares into a total of 54,500 ordinary shares for delivery of shares to participants in the performance-based share saving program that was adopted by the annual general meeting held on 14 November 2019 (LTI 2019).

As of 28 February 2023, the number of shares in Ascelia Pharma AB amounts to 34,871,177 shares, of which 33,722,762 are ordinary shares with one vote each and 1,148,415 are series C shares with 1/10 vote each. The total number of votes in the company amounts to 33,837,603.5.

### Contacts

---

Magnus Corfitzen, CEO  
Email: [moc@ascelia.com](mailto:moc@ascelia.com)  
Tel: +46 735 179 118

Déspina Georgiadou Hedin, CFO and Investor Relations  
Email: [despina.georgiadou@ascelia.com](mailto:despina.georgiadou@ascelia.com)  
Tel: +46 765 697 873

*This information was submitted for publication, through the agency of the contact persons set out above.*

## About Us

---

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance (previously referred to as Mangoral) and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit <http://www.ascelia.com>.

### **About Orviglance** (previously referred to as Mangoral)

Orviglance (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, which has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA), is currently in Phase 3 development, including the global multi-center SPARKLE study.

### **About Oncoral**

Oncoral is a novel irinotecan chemotherapy tablet developed initially for the treatment of gastric cancer. Irinotecan chemotherapy has an established potent anti-tumor effect. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following the daily dosing at home compared to intravenous high-dose infusions at the hospital. Following successful Phase 1 results, Oncoral is now prepared for Phase 2 clinical development.

*This information is information that Ascelia Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-02-28 08:00 CET.*

## Attachments

---

### **Change in number of shares and votes in Ascelia Pharma AB**